Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment

Drug repositioning refers to new uses for existing drugs outside the scope of the original medical indications. This approach fastens the process of drug development allowing fnding efective drugs with reduced side efects and lower costs. Colorectal cancer (CRC) is often diagnosed at advanced stages...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anselmino, L. E., Baglioni, M. V., Malizia, Florencia, Cesatti Laluce, N., Borini Etichetti, Carla María, Martínez Marignac, V. L., Rozados, Viviana, Scharovsky, O. G., Girardini, Javier, Rico, M. J., Menacho Márquez, Mauricio
Formato:	article artículo publishedVersion
Lenguaje:	Inglés
Publicado:	Nature Research 2022
Materias:	Drug repositioning Drug therapy Epithelial-Mesenchymal transition Drug effects Triple negative breast neoplasms
Acceso en línea:	http://hdl.handle.net/2133/23319 http://hdl.handle.net/2133/23319
Aporte de:	Repositorio Hipermedial de la Universidad Nacional de Rosario (UNR) de Universidad Nacional de Rosario

id	I15-R121-2133-23319
record_format	dspace
institution	Universidad Nacional de Rosario
institution_str	I-15
repository_str	R-121
collection	Repositorio Hipermedial de la Universidad Nacional de Rosario (UNR)
language	Inglés
topic	Drug repositioning Drug therapy Epithelial-Mesenchymal transition Drug effects Triple negative breast neoplasms
spellingShingle	Drug repositioning Drug therapy Epithelial-Mesenchymal transition Drug effects Triple negative breast neoplasms Anselmino, L. E. Baglioni, M. V. Malizia, Florencia Cesatti Laluce, N. Borini Etichetti, Carla María Martínez Marignac, V. L. Rozados, Viviana Scharovsky, O. G. Girardini, Javier Rico, M. J. Menacho Márquez, Mauricio Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment
topic_facet	Drug repositioning Drug therapy Epithelial-Mesenchymal transition Drug effects Triple negative breast neoplasms
description	Drug repositioning refers to new uses for existing drugs outside the scope of the original medical indications. This approach fastens the process of drug development allowing fnding efective drugs with reduced side efects and lower costs. Colorectal cancer (CRC) is often diagnosed at advanced stages, when the probability of chemotherapy resistance is higher. Triple negative breast cancer (TNBC) is the most aggressive type of breast cancer, highly metastatic and difcult to treat. For both tumor types, available treatments are generally associated to severe side efects. In our work, we explored the efect of combining metformin and propranolol, two repositioned drugs, in both tumor types. We demonstrate that treatment afects viability, epithelial-mesenchymal transition and migratory potential of CRC cells as we described before for TNBC. We show that combined treatment afects diferent steps leading to metastasis in TNBC. Moreover, combined treatment is also efective preventing the development of 5-FU resistant CRC. Our data suggest that combination of metformin and propranolol could be useful as a putative adjuvant treatment for both TNBC and CRC and an alternative for chemo-resistant CRC, providing a low-cost alternative therapy without associated toxicity.
format	article artículo publishedVersion
author	Anselmino, L. E. Baglioni, M. V. Malizia, Florencia Cesatti Laluce, N. Borini Etichetti, Carla María Martínez Marignac, V. L. Rozados, Viviana Scharovsky, O. G. Girardini, Javier Rico, M. J. Menacho Márquez, Mauricio
author_facet	Anselmino, L. E. Baglioni, M. V. Malizia, Florencia Cesatti Laluce, N. Borini Etichetti, Carla María Martínez Marignac, V. L. Rozados, Viviana Scharovsky, O. G. Girardini, Javier Rico, M. J. Menacho Márquez, Mauricio
author_sort	Anselmino, L. E.
title	Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment
title_short	Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment
title_full	Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment
title_fullStr	Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment
title_full_unstemmed	Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment
title_sort	repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment
publisher	Nature Research
publishDate	2022
url	http://hdl.handle.net/2133/23319 http://hdl.handle.net/2133/23319
work_keys_str_mv	AT anselminole repositioningmetforminandpropranololforcolorectalandtriplenegativebreastcancerstreatment AT baglionimv repositioningmetforminandpropranololforcolorectalandtriplenegativebreastcancerstreatment AT maliziaflorencia repositioningmetforminandpropranololforcolorectalandtriplenegativebreastcancerstreatment AT cesattilalucen repositioningmetforminandpropranololforcolorectalandtriplenegativebreastcancerstreatment AT borinietichetticarlamaria repositioningmetforminandpropranololforcolorectalandtriplenegativebreastcancerstreatment AT martinezmarignacvl repositioningmetforminandpropranololforcolorectalandtriplenegativebreastcancerstreatment AT rozadosviviana repositioningmetforminandpropranololforcolorectalandtriplenegativebreastcancerstreatment AT scharovskyog repositioningmetforminandpropranololforcolorectalandtriplenegativebreastcancerstreatment AT girardinijavier repositioningmetforminandpropranololforcolorectalandtriplenegativebreastcancerstreatment AT ricomj repositioningmetforminandpropranololforcolorectalandtriplenegativebreastcancerstreatment AT menachomarquezmauricio repositioningmetforminandpropranololforcolorectalandtriplenegativebreastcancerstreatment
bdutipo_str	Repositorios
_version_	1764820411971796993

Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment

Ejemplares similares